An ECDC expert opinion concludes that there is clear evidence supporting the use of neuraminidase inhibitors in the treatment and prevention of influenza. Moreover, the current recommendations in European countries on the use of the neuraminidase inhibitors oseltamivir and zanamivir are appropriate and should be applied by prescribing physicians.

A new ECDC Evidence Brief summarises many of the key issues across Europe regarding implementation of PrEP and provides some options for action. It draws on country data reported to ECDC for Dublin Declaration monitoring in 2016.​​​

The results of two clinical studies, PROUD and IPERGAY, suggests that the use of pre-exposure prophylaxis (PrEP) for men who have sex with men (MSM) is an effective HIV prevention tool for Europe.

The use of pre-exposure prophylaxis (PrEP) as an HIV prevention strategy, particularly among men who have sex with men (MSM) as well as other population groups at higher risk of HIV infection, has been receiving more and more attention during 2014. Preliminary results of clinical trials and research studies suggest that it could be an effective HIV prevention tool for Europe.

This evaluated patients admitted to hospital with laboratory-confirmed or clinically diagnosed influenza A H1N1pdm09 virus infection.

This study assessed the effectiveness of within household oseltamivir treatment of a large number of people with seasonal influenza on reducing the duration of clinical illness and viral shedding in cases and the transmission to household contacts.

Two evaluations have recently been published looking at ‘micro’ and ‘macro’ attempts to contain the 2009 pandemic influenza in Singapore and the UK respectively with seeming differing outcomes.

In February 2010 WHO published its Guidelines for Pharmacological Management of Pandemic (H1N1) 2009 Influenza and other Influenza Viruses.